2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Albireo: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Odevixibat, Placebo - Alagille Syndrome | Phase 3 | Completed | Albireo | 52 | 2021-03-19 | 2023-11-02 |
| This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2 A4250 (odevixibat), Placebo - PFIC1, PFIC2 | Phase 3 | Completed | Albireo | 62 | 2018-05-16 | 2025-11-28 |
Alagille Syndrome (1) · Cholestasis (1)
odevixibat (2)
Belgium (2) · Canada (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Poland (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Australia (1) · Malaysia (1) · New Zealand (1) · Saudi Arabia (1)